尤瑞克林联合静脉溶栓治疗急性脑梗塞的临床疗效及对血浆血小板、D-D、Fg水平的影响

目的:探讨尤瑞克林联合静脉溶栓治疗急性脑梗塞的临床疗效及对血浆血小板、D-二聚体(D-D)、纤维蛋白原(Fg)水平的影响。方法:选择2015年5月至2018年5月我院接诊的急性脑梗塞患者65例作为研究对象,根据随机数表法分为观察组(n=35)和对照组(n=30)。对照组采用静脉溶栓治疗,观察组采用尤瑞克林联合静脉溶栓治疗。比较两组治疗后的临床疗效,治疗前后血浆血小板、D-D、Fg、美国国立卫生研究院卒中量表(NIHSS)评分、改良Barthel指数评定量表(MBI)水平的变化及不良反应的发生情况。结果:治疗后,观察组临床疗效总有效率为94.29%,显著高于对照组(73.33%,P0.05)。两组患者治疗前血浆血小板、D-D、Fg水平、NIHSS、MBI评分比较差异均无统计学意义(P0.05);治疗后,两组患者血浆血小板、D-D、Fg水平及NIHSS评分均较治疗前明显降低,且观察组患者以上指标均显著低于对照组(P0.05);两组患者治疗治疗后MBI评分均较治疗前显著升高,且观察组MBI评分显著高于对照组(P0.05)。两组患者不良反应总发生率分别为2.86%、13.33%,组间比较差异无统计学意义(P0.05)。结论:尤瑞克林联合静脉溶栓治疗急性脑梗塞患者的临床效果显著优于单用静脉溶栓治疗,这可能与其更有效改善改善患者血浆血小板、D-D、Fg水平有关。

Curative Efficacy of Eureklin Combined with Intravenous Thrombolysis in the Treatment of Acute Cerebral Infarction and Its Effects on the Plasma Platelet, D-D, Fg Levels

ABSTRACT Objective: To study the curative efficacy of Eureklin combined with intravenous thrombolysis in the treatment of acute cerebral infarction and its effects on the plasma platelet, D- dimer (D-D), fibrinogen (Fg) levels. Methods: 65 cases of patients with acute cerebral infarction treated in our hospital from May 2015 to May 2018 were selected as the subjects, The patients were divided into the observation group (n=35) and the control group (n=30) according to the random number table method. The control group was given intravenous thrombolysis, and the observation group was treated by intravenous thrombolysis on the basis of control group. The clinical efficacy after treatment, the changes of plasma platelet, D-D, Fg, NIHSS score, modified barbi index rating scale (MBI) before and after treatment and the occurrence of adverse reactions were compared between two groups. Results: After treatment, the total effective rate of observation group was 94.29%, which was significantly higher than that of the control group (73.33%, P<0.05). There was no significant difference in the plasma platelet, D-D, Fg level, NIHSS, MBI scores between the two groups before treatment (P>0.05). After treatment, the plasma platelets, D-D, Fg levels and NIHSS scores in both groups were significantly lower than before treatment, and the above indicators in the observation group were significantly lower than those in the control group (P < 0.05). MBI scores of patients in both groups were significantly higher after treatment than before treatment, and the MBI scores in the observation group were significantly higher than those in the control group (P<0.05). The total incidence of adverse reactions in the two groups was 2.86% and 13.33%, respectively, with no statistically significant difference between the two groups (P>0.05). Conclusion: The clinical effect of intravenous thrombolysis combined with eureklin is significantly better than that of intravenous thrombolysis alone in the treatment of acute cerebral infarction patients, which may be related to the more effective improvement of plasma platelet, D-D and Fg levels of patients.